Nausea and vomiting are common symptoms arising from activation of the vomiting center in the medulla oblongata through multiple afferent pathways including the chemoreceptor trigger zone, gastrointestinal vagal afferents, vestibular system, and higher cortical centers. Antiemetic drugs target these distinct pathways, allowing a tailored approach to therapy based on the underlying cause.
What Are Antiemetics?
Antiemetics are classified by their primary receptor target, which determines their efficacy in specific clinical contexts. Choosing the correct agent depends on the etiology of nausea and vomiting, whether from chemotherapy, postoperative causes, motion sickness, pregnancy, or gastroenteritis.
Drug Classes and Mechanisms
5-HT3 antagonists including ondansetron, granisetron, and palonosetron block serotonin receptors in the gut and chemoreceptor trigger zone. They are highly effective for chemotherapy-induced and postoperative nausea and vomiting and have a favorable safety profile with headache and constipation as the main side effects.
Neurokinin-1 antagonists such as aprepitant and fosaprepitant block substance P at NK1 receptors in the vomiting center. They are used primarily in combination with 5-HT3 antagonists and corticosteroids for highly emetogenic chemotherapy, particularly cisplatin-based regimens.
Dopamine antagonists include metoclopramide, domperidone, and prochlorperazine. Metoclopramide also has prokinetic effects via 5-HT4 agonism, making it useful in gastroparesis and migraine-associated nausea. Domperidone does not cross the blood-brain barrier readily, reducing central nervous system side effects. Prochlorperazine is a phenothiazine effective for a range of emetic stimuli.
Antihistamines such as meclizine, dimenhydrinate, and diphenhydramine block H1 receptors in the vestibular system. They are first-line for motion sickness and useful in vertigo-associated nausea, though sedation limits their use.
Anticholinergic agents, specifically scopolamine, block muscarinic receptors in the vestibular nuclei. The transdermal patch formulation provides sustained protection against motion sickness for up to three days.
Corticosteroids like dexamethasone have antiemetic effects through poorly understood mechanisms involving prostaglandin inhibition and modulation of neurotransmitter release. They are used adjunctively in chemotherapy-induced nausea.
Cannabinoids including dronabinol and nabilone act on CB1 receptors in the vomiting center. They are reserved for refractory cases due to psychoactive effects.
Therapeutic Uses
Chemotherapy-induced nausea and vomiting is managed by risk stratification: highly emetogenic regimens receive triple therapy with a 5-HT3 antagonist, NK1 antagonist, and dexamethasone. Motion sickness prophylaxis begins with antihistamines or scopolamine before exposure. Nausea in pregnancy typically responds to pyridoxine-doxylamine combinations. Postoperative nausea and vomiting prophylaxis targets high-risk patients with 5-HT3 antagonists or droperidol.
Adverse Effects
5-HT3 antagonists may cause QTc prolongation at high doses. Metoclopramide carries a black box warning for tardive dyskinesia with prolonged use. Antihistamines cause sedation and anticholinergic effects. Scopolamine causes dry mouth, blurred vision, and urinary retention. Corticosteroids should not be used long term for antiemetic purposes due to systemic adverse effects.
Key Clinical Considerations
Identifying the emetic pathway involved guides appropriate agent selection. Combination therapy targeting multiple receptors is superior in highly emetogenic settings. Metoclopramide use should be limited to short durations due to extrapyramidal risk. QT interval monitoring is warranted when combining serotonergic antiemetics with other QT-prolonging drugs.
Conclusion
Antiemetic therapy is most effective when directed at the specific mechanism driving nausea and vomiting. Understanding the receptor pharmacology underlying different emetic stimuli enables rational drug selection and combination strategies for optimal symptom control.
